What it is
Lixisenatide is a GLP-1 receptor agonist — a peptide that switches on the same receptor as the gut hormone GLP-1. It is 44 amino acids long with an amide group at the end (Soliqua label; ChEBI), and PubChem records it as C215H347N61O65S, molecular weight 4,858 (CID 90472060).
It is built on exendin-4, a 39-amino-acid peptide from the saliva of the Gila monster (Heloderma suspectum). PubChem's systematic synonym spells out the two changes: "DesPro38Exendin-4(1-39)-Lys6-NH2" — proline 38 removed, and six lysines added to the tail:
| Exendin-4 / exenatide | Lixisenatide | |
|---|---|---|
| Length | 39 amino acids | 44 amino acids |
| Residue 38 | proline | removed |
| Tail | ends …P-P-S | ends …P-P-S-K-K-K-K-K-K-NH2 |
| Library entry | exenatide | this page |
The other 38 residues are shared, which is why the two drugs are often grouped as the "exendin-based" GLP-1 agonists, apart from the human-based liraglutide and semaglutide.
How it works
The Soliqua label states the mechanism in one line: lixisenatide increases glucose-dependent insulin release, decreases glucagon secretion and slows gastric emptying. "Glucose-dependent" means the insulin effect is larger when blood sugar is high, which is the general property of the GLP-1 system and of the wider incretin family. In Soliqua its peak in blood comes 2.5 to 3 hours after the injection, and 55% of it is bound to plasma proteins (label section 12.3).
What the evidence shows
Blood sugar. Soliqua's current label leads with Study A (NCT05058147): 1,170 adults with type 2 diabetes on metformin, 30 weeks, open-label.
| Arm | Patients | HbA1c start → end | Change |
|---|---|---|---|
| Soliqua (glargine + lixisenatide) | 469 | 8.1 → 6.5% | −1.6 |
| Insulin glargine alone | 467 | 8.1 → 6.8% | −1.3 |
| Lixisenatide alone | 233 | 8.1 → 7.3% | −0.9 |
Read across the rows, lixisenatide on its own lowered HbA1c the least of the three arms; its role in this product is as an add-on to basal insulin.
The heart. ELIXA (NEJM 2015, PMID 26630143; funded by Sanofi) randomised 6,068 people with type 2 diabetes who had had a heart attack or unstable angina in the previous 180 days. Over a median 25 months the primary composite — cardiovascular death, heart attack, stroke or hospitalisation for unstable angina — occurred in 13.4% on lixisenatide and 13.2% on placebo (hazard ratio 1.02, 95% CI 0.89–1.17). That met the non-inferiority bound and failed superiority (P = 0.81); heart-failure admissions (HR 0.96) and deaths (HR 0.94) did not differ.
Parkinson's disease. LixiPark (NEJM 2024, PMID 38598572) gave daily lixisenatide or placebo to 156 people diagnosed with Parkinson's less than three years earlier. At 12 months the motor score (MDS-UPDRS part III) had changed by −0.04 points on the drug and +3.04 on placebo, a difference of 3.08 (95% CI 0.86–5.30, P = 0.007). Other secondary end points did not differ much, nausea occurred in 46% and vomiting in 13%, and the authors wrote that longer and larger trials are needed. It is one phase 2 trial; it does not make lixisenatide a Parkinson's treatment.
What is not established: any weight-management indication (none of its labels carries one), any cardiovascular benefit, and any disease-modifying effect in Parkinson's beyond this single trial.
Where it stands
Lixisenatide was approved in the US in 2016 — Adlyxin on 27 July (BLA 208471) and Soliqua 100/33 on 21 November (BLA 208673). On 2026-11-18 openFDA held a current Soliqua label (effective 2026-03-18) and no Adlyxin label; this entry does not infer from that why. Soliqua's label limits it to adults with type 2 diabetes and states that combining it with any other product containing a GLP-1 receptor agonist is not recommended. Its warnings include anaphylaxis, pancreatitis, hypoglycaemia, acute kidney injury from fluid loss, severe gastrointestinal reactions, gallbladder disease and pulmonary aspiration under anaesthesia.
The library's insulin entry covers the other half of Soliqua; pramlintide is another peptide given alongside insulin.
Sources opened 2026-11-18: Soliqua 100/33 label (openFDA, effective 2026-03-18: sections 1, 2, 5, 6, 11, 12, 14); Drugs@FDA records for BLA 208471 and BLA 208673; PubChem CID 90472060 (properties, ChEBI description, synonyms); Pfeffer 2015, NEJM (ELIXA, PMID 26630143, abstract); Meissner 2024, NEJM (LixiPark, PMID 38598572, abstract); PubMed E-utilities and ClinicalTrials.gov API v2 counts.
